– UK, London – AstraZeneca PLC (LSE:AZN), today announced that Philip Broadley will be proposed to shareholders for election as a Non-Executive Director of AstraZeneca PLC at the Company’s Annual General Meeting on 27 April 2017. On election, the Board proposes appointing Mr Broadley as a member of the Audit Committee.
Ann Cairns, a Non-Executive Director, will step down from the AstraZeneca Board and as a member of the Audit Committee with effect from the end of the AGM on 27 April 2017.
Leif Johansson, Chairman of AstraZeneca, said: “On behalf of the Board, I’d like to thank Ann for her contribution to AstraZeneca, both as a Board member and as a member of the Audit Committee over the last three years. We wish her all the best for the future. I’m delighted that the Board is proposing Philip Broadley for election as a Non-Executive Director. His significant international business and financial experience will prove a valuable addition to the Board and we look forward to welcoming him.”
About Philip Broadley
Philip has significant financial and international business experience, having previously been Group Finance Director of Prudential plc for eight years until 2008 and of Old Mutual plc for six years until 2014. He started his career at Arthur Andersen where he was a partner for seven years. He is a past Chairman of the 100 Group of Finance Directors in the UK. He is a Fellow of the Institute of Chartered Accountants in England and Wales. He graduated in Philosophy, Politics and Economics from St Edmund Hall, Oxford and has an MSc in Behavioural Science from the London School of Economics.
Philip is a Non-Executive Director of Legal & General Group plc and chairs its Audit Committee. He is a member of the Code Committee of the UK Takeover Panel. He is a member of the Oxford University Audit Committee, Treasurer of the London Library and a governor of Eastbourne College.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas – Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of Autoimmunity, Neuroscience and Infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
For more information : https://www.astrazeneca.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
